Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?-Reference-Cited by-同舟云学术

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

Published:2022-11 Issue: Volume:176 Page:164-167
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Di Noia Vincenzo,Pimpinelli Fulvia,Renna Davide,Campo Flaminia,Cosimati Antonella,Torchia Andrea,Marcozzi Benedetta,Massacci Alice,Pallocca Matteo,Pellini Raul,Morrone Aldo,Cognetti Francesco

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution;Di Noia;Clin Cancer Res,2021

2. Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer;Di Noia;Annals of Oncology,2022

3. Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after 6-months: the urgent need of the additional dose!;Di Noia;Eur J Cancer,2022

4. Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer;Di Noia;Ann Oncol,2022

5. Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment;Rottenberg;JAMA Oncol,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-sectional survey evaluating the psychological impact of the COVID-19 vaccination campaign in patients with cancer: The VACCINATE study;PLOS ONE;2024-01-25

2. Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments;Diseases;2023-09-26

3. A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers;Vaccines;2023-05-23

4. Refusal of vaccination against influenza and COVID-19 in patients with solid cancers: from bio-ethical issues to solutions;European Journal of Cancer;2023-04